MARKET

IMMP

IMMP

Immutep
NASDAQ
4.150
-0.190
-4.38%
Opening 11:07 10/07 EDT
OPEN
4.310
PREV CLOSE
4.340
HIGH
4.310
LOW
4.130
VOLUME
4.78K
TURNOVER
--
52 WEEK HIGH
70.60
52 WEEK LOW
4.130
MARKET CAP
30.58M
P/E (TTM)
-0.5565
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at IMMP last week (0928-1002)?
Weekly Report · 2d ago
Immutep Limited - Depositary Receipt Price Target Increased by 917.93% to $69.75
NASDAQ · 5d ago
Immutep receives A$856,669 cash rebate from Australia R&D tax incentive program
TipRanks · 09/30 12:25
Immutep Receives A$856,669 Cash Rebate From Australian Federal Government’s R&D Tax Incentive Program
Benzinga · 09/30 12:06
Weekly Report: what happened at IMMP last week (0921-0925)?
Weekly Report · 09/28 09:54
Upcoming Stock Splits This Week (September 28 to October 2) – Stay Invested
TipRanks · 09/27 17:43
Immutep Resets ADS Ratio to Bolster Nasdaq Listing Compliance
TipRanks · 09/22 10:36
Immutep announces 1-for-20 ADS ratio change
Seeking Alpha · 09/21 13:06
More
About IMMP
Immutep Limited is an Australia-based late-stage biotechnology company. The Company is focused on developing novel immunotherapies for cancer and autoimmune disease. It is focused on advancement of therapeutics related to Lymphocyte Activation Gene-3 (LAG-3), and its diversified product portfolio harnesses LAG-3’s ability to stimulate or suppress the immune response. Its lead clinical candidate is eftilagimod alfa (efti or IMP321) for the treatment of different types of cancers. Efti is the Company’s first-in-class novel immunotherapy that directly activates the immune system to fight cancer, which is under evaluation in TACTI-004 (KEYNOTE-F91), a registrational Phase III trial for the first-line therapy of advanced or metastatic non-small cell lung cancer. Its second in-house product candidate (IMP761) which is in clinical development for the treatment of autoimmune disease, a third product candidate, IMP731, a depleting antibody that could remove T cells involved in autoimmunity.

Webull offers Immutep Ltd - ADR stock information, including NASDAQ: IMMP real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, IMMP stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading IMMP stock methods without spending real money on the virtual paper trading platform.